Thermo Fisher Scientific PP&E Sale Proceeds increased by 575.0% to $27.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 58.8%, from $17.00M to $27.00M. Over 4 years (FY 2021 to FY 2025), PP&E Sale Proceeds shows an upward trend with a 21.8% CAGR.
An increase provides a one-time cash boost and may indicate a shift in strategy or the decommissioning of obsolete infrastructure.
The cash inflows received from the disposal or sale of property, plant, and equipment. This includes the liquidation of...
Analyzed alongside capital expenditures to determine the net investment in physical footprint.
cf_proceeds_from_sale_of_ppe| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $4.00M | $11.00M | $2.00M | $12.00M | $4.00M | $6.00M | $6.00M | $4.00M | $66.00M | $11.00M | $4.00M | $16.00M | $20.00M | $17.00M | $12.00M | $1.00M | $4.00M | $27.00M |
| QoQ Change | — | — | +175.0% | -81.8% | +500.0% | -66.7% | +50.0% | +0.0% | -33.3% | >999% | -83.3% | -63.6% | +300.0% | +25.0% | -15.0% | -29.4% | -91.7% | +300.0% | +575.0% |
| YoY Change | — | — | — | — | — | +0.0% | -45.5% | +200.0% | -66.7% | >999% | +83.3% | -33.3% | +300.0% | -69.7% | +54.5% | +200.0% | -93.8% | -80.0% | +58.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.